[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585088":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"WD-910 Take a fixed dose of WD-910 tablets orally","EXPERIMENTAL",null,[13],"Drug: WD-910 tablet",{"label":15,"type":10,"description":11,"interventionNames":16},"WD-910 Tablets Placebo Take a fixed dose of WD-910 tablets Placebo orally",[17],"Drug: WD-910 Tablets Placebo",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","WD-910 tablet","Administered P.O.",[9],{"type":20,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"WD-910 Tablets Placebo",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Arockiaa Joseph","CONTACT","+61 459 661 281","c.trollip@nucleusnetwork.com.au",[34],{"facility":35,"status":11,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Nucleus Network Pty Ltd","Melbourne","Victoria","3004","Australia","AU",{"type":42,"coordinates":43},"Point",[44,45],144.96332,-37.814,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":31,"phoneExt":11,"email":32},"Joseph",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100585088","phase-1-a-phase-i-randomised-double-blind-placebo-controlled-single-and-multiple-ascending-dose-study-to-evaluate-the-safety-tolerability-pharmacokinetics-pharmacodynamics-and-food-effect-of-wd-910-in-healthy-participants-100585088",false,"NCT06897813","A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants","Inclusion Criteria:\n\n* Aged 18 to 55 years (inclusive) at the time of informed consent.\n* Body mass index (BMI) between 18 to 32 kg\u002Fm2 and male participant with body weight of ≥ 50.0 kg, female participant with body weight ≥ 45.0 kg\n\nExclusion Criteria:\n\n* Any major surgery within 12 weeks prior to Day 1, or any planned surgery during the study.\n* Poor pill swallowing ability",true,"ALL","18 Years","55 Years",{"count":63,"type":64},68,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed",[70],"Healthy Participants","NOT_YET_RECRUITING","2025-03-26",{"date":74,"type":75},"2025-04-02","ACTUAL",{"date":77,"type":64},"2025-06-30",{"date":79,"type":64},"2025-12-31",{"name":5,"class":6},1]